GlassScriptPhysician profile
Jack T Hall
NPI 1669930145
$5,633.98
in general payments reported to CMS, 2019-2025
39 companies · $187 in 2025
The $187 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,600 · 2022: $1,772 · 2023: $1,258 · 2024: $817 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,261.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $727.96 | 2021-2024 | Lifevest |
| Amgen INC. | $614.35 | 2021-2024 | Repatha |
| Abbott Laboratories | $598.83 | 2021-2024 | Cardiomems |
| Janssen Pharmaceuticals, INC | $544.32 | 2021-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $454.05 | 2021-2024 | |
| Pfizer INC. | $328.64 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.16 | 2021-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $223.75 | 2021-2023 | |
| United Therapeutics Corporation | $219.53 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $215.41 | 2022-2024 | Camzyos |
| Merck Sharp & Dohme LLC | $184.24 | 2022-2024 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $180.71 | 2022-2023 | Opsumit, Uptravi |
| Inspire Medical Systems, INC. | $124.85 | 2024 | Inspire |
| Lexicon Pharmaceuticals, INC. | $103.48 | 2023-2024 | Inpefa |
| Edwards Lifesciences Corporation | $88.75 | 2021 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $77.77 | 2023 | Amvuttra |
| Astrazeneca Pharmaceuticals LP | $66.53 | 2022-2024 | Wainua |
| Esperion Therapeutics, INC. | $62.05 | 2021-2024 | Nexletol |
| Sumitomo Pharma America, INC. | $60.98 | 2024-2025 | Gemtesa, Orgovyx |
| Masimo Corporation | $55.13 | 2022-2023 | Set and Rainbow Set |
| Endo USA, INC. | $47.13 | 2025 | Aveed, Xiaflex |
| Medtronic, INC. | $44.77 | 2021-2022 | |
| Akcea Therapeutics, INC. | $40.57 | 2021 | |
| Baxter Healthcare | $33.03 | 2023 | Coseal |
| Procept Biorobotics Corporation | $32.35 | 2025 | |
| Genzyme Corporation | $27.58 | 2025 | |
| 180 Medical, INC. | $27.47 | 2024 | Gentlecath |
| Zoll Circulation INC | $22.88 | 2023 | Downstream Cartridge, Therox Ds2 Console, Catheter |
| Janssen Biotech, INC. | $22.66 | 2025 | Tremfya |
| Kiniksa Pharmaceuticals International, Plc | $21.76 | 2024 | Arcalyst |
| Irhythm Technologies, INC. | $20.25 | 2023 | Zio Xt Patch |
| Novo Nordisk INC | $20.02 | 2024 | Rybelsus, Ozempic |
| Progenics Pharmaceuticals, INC. | $19.13 | 2025 | |
| Teleflex LLC | $17.75 | 2023 | Manta |
| Kiniksa Pharmaceuticals, LTD. | $17.65 | 2023 | Arcalyst |
| Inogen, INC. | $17.33 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Amarin Pharma, INC. | $16.26 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.62 | 2024 | |
| Boston Scientific Corporation | $14.28 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.